AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06600906 — intervention group
Intervention type: PROCEDURE
Intervention: Computed tomography (CT)
Description: Undergo CT imaging
Study NCT06600906 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI imaging
Study NCT04553094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle building training
Description: Muscle strengthening circuit training
Study NCT04375046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)
Description: In this study, the experimental group will receive 0.4 mg/kg rbACE2 IV
Study NCT04402242 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bispectral index
Description: Anesthesia monitoring
Study NCT04402242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index + NOL index
Description: Anesthesia monitoring
Study NCT00000935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Description: given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
Study NCT00000935 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immune globulin (IVIG)
Description: given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
Study NCT05866224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program
Description: The supervised telerehabilitation program will be performed in the home of each patient and supervised by an experienced physiotherapist with more than 4 years of clinical experience in therapeutic exercise for chronic diseases.
Study NCT05193721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1901
Description: SHR-1901 dose escalation at 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg
Study NCT04786470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine infusion via transversus abdominis plane catheter.
Study NCT04786470 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline infusion via transversus abdominis plane catheter.
Study NCT06476795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chardonnay Marc
Description: Food product made from Chardonnay wine grapes
Study NCT04739683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley bulb placement
Description: A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.
Study NCT04739683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DILAPAN-S® placement
Description: A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
Study NCT05580640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT
Description: For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
Study NCT06657573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An AI-enabled chatbot tailored for influenza vaccine consultation
Description: The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.
Study NCT06656182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical and Thoracic SNAGs
Description: cervical SNAGs (C3-C7) and thoracic SNAGs (T1-T12) with 6 repetitions of 1 set three times per week for 4 weeks along with scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
Study NCT06656182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy and scapular mobilizations
Description: scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
Study NCT06656624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib combined with AI±OFS
Description: Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
Study NCT06656624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS
Description: Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
Study NCT06656598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
Study NCT06656598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
Study NCT06656598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
Study NCT06656598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
Study NCT06656598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).
Study NCT06656598 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Curative hypofractionated radiotherapy
Description: Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
Study NCT06656598 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Curative hypofractionated radiotherapy
Description: Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
Study NCT06656598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab (maintenance)
Description: Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
Study NCT06656598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab (maintenance)
Description: Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
Study NCT06657625 — intervention group
Intervention type: OTHER
Intervention: Sepsis Performance Improvement Program
Description: Training/awareness for medical and paramedical staff; creation of informational posters; development of an institutional pathway in the emergency department; creation of a protocol ; establishment of a sepsis team with a dedicated contact number.
Study NCT06587256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Tape
Description: A single piece of silicone tape placed vertically over the lips. When positioned properly the participant can still inhale/exhale and cough around the tape if needed, but will tend to keep mouth closed otherwise.
Study NCT04728204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depresijos terapija
Description: Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
Study NCT04708067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT04708067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04708067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT05516914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007 Injection
Description: Initial dose - MTD; Q3W; intravenous infusion
Study NCT05516914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: Initial dose; Q3W; intravenous infusion
Study NCT05516914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: Initial dose；Q3W; intravenous infusion
Study NCT05516914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride for Injection
Description: Initial dose；Q3W; intravenous infusion
Study NCT05516914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: Initial dose；Q3W; intravenous infusion
Study NCT06533592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continous suture technique
Description: Duct-to-duct anastomosis will be performed using continuous suture technique for study group
Study NCT06533592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture technique
Description: Duct-to-duct anastomosis will be performed using an interrupted suture for control group,
Study NCT05526534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidified high flow nasal cannula oxygen therapy, HFNC
Description: HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.
Study NCT05526534 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal cannula oxygen
Description: Nasal cannula oxygen has become a routine part of postoperative treatment
Study NCT05902728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
Study NCT05902728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
Study NCT05902728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: 450 mg
Study NCT05902728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: 900 mg
Study NCT05902728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: 200 mg
Study NCT05902728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600mg
Study NCT05775653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADAPT program
Description: The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.
Study NCT05775653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UOT
Description: UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
Study NCT05707169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Ablation
Description: Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.
Study NCT05707169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endogenous Laser Ablation (EVLA)
Description: Endogenous Laser Ablation (EVLA)
Study NCT05707169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
Description: mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
Study NCT04916678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R-TEP EMDR intervention
Description: During the intervention period, trained psychologists are available in the ER and will provide preferentially a short early 1-hour R-TEP EMDR intervention for patients selected with high risk of PCLS. Patient's selection will be conducted using a score developed in previous studies. If therapist considers R-TEP EMDR unsuitable, he could provide another type of intervention (such as reassurance) that will be recorded.~When no high-risk patient is identified, the therapist could assess other patients and treat them if judged necessary. In this context, they could provide either a R-TEP EMDR or short intervention such as reassurance according to therapist assessment.
Study NCT06441799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home radiofrequency skin treatment instrument
Description: Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
Study NCT06441799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasonic coupler for medical purposes
Description: In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
Study NCT05491122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing or decreasing daily total fluid intake
Description: 1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
Study NCT05452603 — intervention group
Intervention type: DEVICE
Intervention: 96-hour off IBP wireless pH monitoring capsule
Description: The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
Study NCT05634577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitotane
Description: Given by PO
Study NCT05634577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)
Study NCT06271473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
Description: vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
Study NCT05803603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stipend and Social Work Supports
Description: Same as arm description
Study NCT06412016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Nutritional Counseling + Urban Gardening
Description: Peer nutritional counseling and urban gardens
Study NCT06504056 — intervention group
Intervention type: BIOLOGICAL
Intervention: Diagnosis of NVM
Description: The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
Study NCT05118412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lucerne protein concentrate shake
Description: At three out of five test days: Lucerne protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
Study NCT05118412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate shake
Description: At two out of five test days: Whey protein concentrate powder will be mixed with water to obtain a shake, representing a 20g protein load.
Study NCT05135364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
Study NCT05135364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks
Study NCT05135364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: Lenvatinib or Regorafenib
Study NCT05741021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
Study NCT05741021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: A chemotherapy medication used to treat a number of types of cancer.
Study NCT05741021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A chemotherapy medication used to treat a number of types of cancer.
Study NCT05741021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
Study NCT06545864 — intervention group
Intervention type: DRUG
Intervention: Streptokinase Injection
Description: 250000 IU as a loading dose over 30 min. Followed by 100000 IU/hour over 12:24hours or accelerated regimen 1.5 million IU over 2 hours
Study NCT06545864 — intervention group
Intervention type: DEVICE
Intervention: Penumbra System
Description: which comprised of several devices:~* RED Reperfusion Catheters~* Penumbra JET Reperfusion Catheters~* ACE Reperfusion Catheters~* MAX Reperfusion Catheters~* 3D Revascularization Device~* Penumbra ENGINE Aspiration Source~* Penumbra ENGINE Canister~* Aspiration Tubing
Study NCT05327738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05327738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05327738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05327738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given intra-arterially
Study NCT06551558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global warming
Description: A systematic pre- and post-operative warming associated with the optimization of per-operative warming.